Amidst concern that stimulant medications used to treat attention deficit hyperactivity disorder (ADHD) could present a cardiac risk, a new study reviews the historic use of the medications and the dangers that have been observed.
Investigators discovered short-term stimulant treatment did not substantially increase the risk of cardiovascular events or symptoms in healthy youth.
ADHD affects 5-9 percent of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure.
In the study, Dr. Mark Olfson and his colleagues assessed the risk of adverse cardiovascular events in children and adolescents without known heart conditions treated with stimulants for attention deficit hyperactivity disorder.
The investigation is one of the largest studies to date that focused primarily on youth while controlling for pre-existing cardiovascular risk factors.
As reported in the study, Olfson and colleagues examined claims records from a large privately insured population for associations between cardiovascular events in youth with ADHD and stimulant treatment.
In total 171,126 privately insured youth aged 6-21 years without known pre-existing heart-related risk factors were followed throughout the study.
Researchers included patients who have previously received stimulant treatment, patients currently receiving stimulant treatment, and patients who began or ceased stimulant treatments during the study period.
Olfson and colleagues assessed the various groups for incidents of severe cardiovascular events such as acute myocardial infarction, less severe cardiovascular events such as cardiac dysrhythmias, and cardiovascular symptoms such as tachycardia and palpitations.
Analysis showed that cardiovascular events and symptoms were rare in this cohort and not associated with stimulant use.
This finding helps to allay concerns of adverse events in otherwise healthy young people receiving treatment for ADHD. Olfson and colleagues said of the results, “It is reassuring that in these young people, short-term stimulant treatment did not substantially increase the risk of cardiovascular events or symptoms.”
The research is published in the Journal of the American Academy of Child and Adolescent Psychiatry.